NACHC Hill Day Document Calls for 340B Reform and Offers Guiding Principles, Key Hill Staffer Joins Organization

NACHC image of core principles for 340B reform
“Health centers and their patients cannot afford more [contract pharmacy] restrictions or PBM discriminatory contracting," NACHC says in document urging Congress "to amend the 340B statute to protect access for the true safety-net providers.”

The National Association of Community Health Centers says in a new advocacy document “it’s time to reform the 340B program to recognize the complexities of today’s healthcare system and ensure that true safety-net providers continue to have access to critical

Read More »

Bottom Line, not Altruism, Could be the Main Driver of Lilly’s Insulin Price Cut, Drug Pricing Expert Says

Humalog vial
Lilly's decision to cut the price of its fast-acting insulin Humalog might have been driven by a desire to avoid exposure to Medicaid rebates, drug pricing expert Sean Dickson says.

Drug manufacturer Lilly’s announcement last week that it is slashing the price of Humalog, its most commonly prescribed insulin, may have been less about altruism and more about avoiding exposure to bigger Medicaid rebates, a prominent drug pricing expert says.

Read More »

Zydus Pharmaceuticals USA Announces Refunds for 340B Overcharges During 2022

Zydus wordmark
Zydus Pharmaceuticals is providing refunds for 340B overcharges during 2022 on 83 NDCs.

Generic drug manufacturer Zydus Pharmaceuticals USA said in a recent public notice it will pay refunds for 340B overcharges that occurred mostly in the first two quarters of 2022. The products include Zydus’ equivalents of the widely prescribed antibiotic Zithromax,

Read More »

News Alert

340B Raised Often During Senate Hearing on Community Health Centers

Sen. Bill Cassidy pictured at a hearing
Sen. Bill Cassidy (R-La.) asked a witness during a hearing if she was open to 340B reforms to ensure that 340B savings “are not going to build a chandelier in a hospital et cetera.”

The 340B program—and whether it needs change, protection, or both—came up often today during a U.S. Senate hearing on federal funding of community health centers.

The bulk of health centers’ federal grant funding—about $5.8 billion annually from the U.S. Health

Read More »

Health Centers and PhRMA Co-Developing 340B Policies, Hospital Group Says

NACHC and PhRMA wordmarks
NACHC and PhRMA are jointly developing 340B policy proposals for Congress to consider, hospital group 340B Health says.

Associations representing community health centers and brand drug manufacturers are jointly developing 340B policy proposals for Congress to consider, hospital group 340B Health told its members yesterday.

The National Association of Community Health Centers said yesterday that it had no

Read More »

Exclusive: HRSA Asking Hospitals About 340B Patient Definition, 340B Savings, and Using 340B at Child Sites

Dept. of Health and Human Services building and signage
Hospital advocates said HRSA's recent decision to end a 340B program waiver for hospitals could draw legal challenges.

UPDATED Thursday March 2, 2023, 12:30 p.m. EDT to include comment from HRSA.

The U.S. Health Resources and Services Administration has asked multiple hospitals to explain how they determine patient eligibility for 340B drugs, how they define, track, and use

Read More »
Industry Insights Logo

Verity Presents: 340B Outlook from Capitol Hill and the States

SPONSORED CONTENT

Will you be attending the 340B Winter Coalition Conference in San Diego? Start your week with the latest developments in the 340B program. This year, Verity Solutions will be hosting a panel

Read More »

Feds Considering Asking Full Appeals Court to Rehear Case Over AstraZeneca, Novo Nordisk, and Sanofi’s 340B Contract Pharmacy Policies

Seal of the U.S. Court of Appeals for the Third Circuit
HHS might ask the full U.S. Third Circuit Court of Appeals to rehear a a lawsuit over AstraZeneca, Novo Nordisk, and Sanofi’s 340B contract pharmacy policies.

The federal government may ask all 14 judges on the U.S. Third Circuit Court of Appeals to review a three-judge panel’s unanimous January opinion upholding AstraZeneca, Novo Nordisk, and Sanofi’s restrictions on 340B pricing when their drugs are shipped to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live